Adicet Reveals Phase 1 Data for Lupus Therapy; Arcus’ ‘Best-in-Class’ Kidney Cancer Drug

Adicet Bio Announces Positive Preliminary Data from ADI-001 Phase 1 Study in Patients with Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE)

REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Oct 7, 2025-

Adicet reveals Phase 1 data for lupus therapy; Arcus’ ‘best-in-class’ kidney cancer drug

Plus, news about AbbVie, BlueRock Therapeutics, MaaT Pharma, Valneva, Jade Biosciences, Affinia Therapeutics, DBV Technologies, Pharming Group and Gemma Bio: 📈 Adicet Bio shares lupus data, initiates stock sale: The company’s cell therapy candidate, called ...